SyrosingopineCAS# 84-36-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 84-36-6 | SDF | Download SDF |
| PubChem ID | 6769 | Appearance | Powder |
| Formula | C35H42N2O11 | M.Wt | 666.71 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | methyl (1R,15S,17R,18R,19S,20S)-17-(4-ethoxycarbonyloxy-3,5-dimethoxybenzoyl)oxy-6,18-dimethoxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate | ||
| SMILES | CCOC(=O)OC1=C(C=C(C=C1OC)C(=O)OC2CC3CN4CCC5=C(C4CC3C(C2OC)C(=O)OC)NC6=C5C=CC(=C6)OC)OC | ||
| Standard InChIKey | ZCDNRPPFBQDQHR-SSYATKPKSA-N | ||
| Standard InChI | InChI=1S/C35H42N2O11/c1-7-46-35(40)48-31-26(42-3)12-18(13-27(31)43-4)33(38)47-28-14-19-17-37-11-10-22-21-9-8-20(41-2)15-24(21)36-30(22)25(37)16-23(19)29(32(28)44-5)34(39)45-6/h8-9,12-13,15,19,23,25,28-29,32,36H,7,10-11,14,16-17H2,1-6H3/t19-,23+,25-,28-,29+,32+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Syrosingopine has selective depleting effect on brain amines is potentiated by combined treatment with disulfiram or fusaric acid, a dopamine beta-hydroxylase inhibitor. 2. Syrosingopine can sensitize cancer cells to metformin and its more potent derivative phenformin far below the individual toxic threshold of each compound, thus, combining syrosingopine and codrugs is a promising therapeutic strategy for clinical application for the treatment of cancer. 3. Syrosingopine has hypotensive properties. |
| Targets | HCV | Antifection | Androgen Receptor | Histone Methyltransferase | NF-kB | Mdm2 |
Syrosingopine Dilution Calculator
Syrosingopine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.4999 mL | 7.4995 mL | 14.999 mL | 29.9981 mL | 37.4976 mL |
| 5 mM | 0.3 mL | 1.4999 mL | 2.9998 mL | 5.9996 mL | 7.4995 mL |
| 10 mM | 0.15 mL | 0.75 mL | 1.4999 mL | 2.9998 mL | 3.7498 mL |
| 50 mM | 0.03 mL | 0.15 mL | 0.3 mL | 0.6 mL | 0.75 mL |
| 100 mM | 0.015 mL | 0.075 mL | 0.15 mL | 0.3 mL | 0.375 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Ophiohayatone C
Catalog No.:BCN3608
CAS No.:84-33-3
- Rutaecarpine
Catalog No.:BCN4385
CAS No.:84-26-4
- Hexestrol
Catalog No.:BCC4484
CAS No.:84-16-2
- Cariprazine
Catalog No.:BCC1453
CAS No.:839712-12-8
- 2,7-Dimethyl-1,4-dihydroxynaphthalene 1-O-glucoside
Catalog No.:BCN7611
CAS No.:839711-70-5
- Pluripotin
Catalog No.:BCC6178
CAS No.:839707-37-8
- GNF-7
Catalog No.:BCC6529
CAS No.:839706-07-9
- 4-Epicommunic acid
Catalog No.:BCN4382
CAS No.:83945-57-7
- Flavidinin
Catalog No.:BCN3599
CAS No.:83925-00-2
- Flavidin
Catalog No.:BCN6438
CAS No.:83924-98-5
- Mometasone furoate
Catalog No.:BCC4801
CAS No.:83919-23-7
- Isogomisin O
Catalog No.:BCN4381
CAS No.:83916-76-1
- Stylopine
Catalog No.:BCN3715
CAS No.:84-39-9
- Tectoquinone
Catalog No.:BCN3481
CAS No.:84-54-8
- Anthraflavic acid
Catalog No.:BCC8831
CAS No.:84-60-6
- Anthraquinone
Catalog No.:BCC8832
CAS No.:84-65-1
- Diisobutyl phthalate
Catalog No.:BCN7148
CAS No.:84-69-5
- Dibutyl Phthalate
Catalog No.:BCC8411
CAS No.:84-74-2
- Lapachol
Catalog No.:BCN4391
CAS No.:84-79-7
- Vitamin K1
Catalog No.:BCN2209
CAS No.:84-80-0
- Xanthoxyletin
Catalog No.:BCN6579
CAS No.:84-99-1
- Fmoc-N-Me-Ala-OH
Catalog No.:BCC3210
CAS No.:84000-07-7
- Fmoc-N-Me-Val-OH
Catalog No.:BCC3358
CAS No.:84000-11-3
- Helioxanthin 8-1
Catalog No.:BCC5415
CAS No.:840529-13-7
Syrosingopine sensitizes cancer cells to killing by metformin.[Pubmed:28028542]
Sci Adv. 2016 Dec 23;2(12):e1601756.
We report that the anticancer activity of the widely used diabetic drug metformin is strongly potentiated by Syrosingopine. Synthetic lethality elicited by combining the two drugs is synergistic and specific to transformed cells. This effect is unrelated to Syrosingopine's known role as an inhibitor of the vesicular monoamine transporters. Syrosingopine binds to the glycolytic enzyme alpha-enolase in vitro, and the expression of the gamma-enolase isoform correlates with nonresponsiveness to the drug combination. Syrosingopine sensitized cancer cells to metformin and its more potent derivative phenformin far below the individual toxic threshold of each compound. Thus, combining Syrosingopine and codrugs is a promising therapeutic strategy for clinical application for the treatment of cancer.
The effect of reserpine, syrosingopine, and guanethidine on the retention of discriminated escape reversal: peripherally administered catecholamines cannot reverse the reserpine amnesia in this situation.[Pubmed:6138025]
Behav Neural Biol. 1983 May;38(1):120-6.
In a series of experiments, the effects of reserpine, Syrosingopine, and guanethidine on retention of a discriminated escape reversal training were investigated in mice. The peripherally and centrally acting reserpine produced amnesia while the primarily peripherally acting compounds, Syrosingopine or guanethidine, did not produce amnesia even when given in high dosages or when training was given with low footshock. Unlike in the passive avoidance situation, peripherally administered norepinephrine or dopamine was not able to attenuate the reserpine-induced amnesia. The results were discussed in terms of the role of biogenic amines in memory formation.
Selective depleting effect of syrosingopine on brain catecholamine levels with relation to morphine analgesia in the rat.[Pubmed:6976]
Pharmacol Biochem Behav. 1976 Apr;4(4):419-25.
Reserpine was the most potent, rescinnamine the next and Syrosingopine the weakest in the depleting effects on brain amines of rauwolfia alkaloids. After Syrosingopine, brain dopamine (DA) was decreased to a smaller degree and with a shorter duration as compared with norepinephrine (NE) and serotonin (5-HT), whereas reserpine elicited a marked and long lasting reduction in these amines. Accordingly, Syrosingopine induced a depletion of brain NE and 5-HT without alteration in brain DA content 2-4 days after administration. Repeated administrations of Syrosingopine, 2 mg/kg daily for 2 or 4 days, resulted in similar alterations in brain amine levels. This selective depleting effect of Syrosingopine on brain amines was potentiated by combined treatment with disulfiram or fusaric acid, a dopamine beta-hydroxylase inhibitor. Under the condition of selective depletion of brain amines induced by repeated administrations of Syrosingopine, 2 mg/kg daily for 2 days, the analgesic action of morphine was not affected, whereas reserpine and tetrabenazine antagonized morphine analgesia, concomitant with inducing a depletion of all brain amines. The results suggest that brain DA may be more important than brain NE or 5-HT with regard to the mechanisms by which morpine produces analgesia.
Effects of amnesic doses of reserpine or syrosingopine on mouse brain acetylcholine levels.[Pubmed:2873591]
Pharmacol Biochem Behav. 1986 May;24(5):1457-9.
The effects of reserpine and Syrosingopine on mouse whole brain acetylcholine levels were examined. At 2 or 24 hr following injection, the brains were removed and analyzed by mass spectrometry. No differences were found between drug-treated and control mice in the acetylcholine content of the brain at either time interval. The results suggest that whole brain acetylcholine levels do not predict the amnesic effects of either reserpine or Syrosingopine.
